



16<sup>th</sup> February 2016

- |  |   |
|--|---|
| <p>(1) BSE Ltd<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> | <p>(2) National Stock Exchange of India Ltd<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> |
|--|---|

**Scrip Code: 500087**

**Scrip Code: CIPLA EQ**

- (3) SOCIETE DE LA BOURSE DE LUXEMBERG  
Societe Anonyme  
11, av de la Porte-Neuve,  
L-2227 Luxemburg

Dear Sirs,

This has reference to our earlier disclosures dated 9<sup>th</sup> July 2015, 20<sup>th</sup> July 2015, 21<sup>st</sup> July 2015, 27<sup>th</sup> November 2015, 10<sup>th</sup> December 2015 and 21<sup>st</sup> January 2016.

We would like to inform you that based on the Press Release dated 15<sup>th</sup> February 2016 issued by the Government of India, Ministry of Finance, Department of Economic Affairs (FIPB Unit), it appears that the Government has based on the recommendations of the Foreign Investment Promotion Board, approved the proposed investment by FIL Capital Investments (Mauritius) II Limited in Cipla Health Limited, subsidiary of the Company.

The investment is still subject to other conditions precedent and the transfer of Company's consumer healthcare business to Cipla Health Limited.

Thank you,

Yours faithfully,  
For Cipla Limited

Mital Sanghvi  
Company Secretary